“Looking ahead, we expect increasing contributions from new products across the portfolio with a balanced mix of iterative and transformative innovation.”

In context

“e several high-growth segments showed an acceleration in growth in the third quarter compared to growth in the first half of this year. And also high single-digit growth in established pharmaceuticals led by double-digit growth in our key 15 markets. Earnings per share rose to $1.30, up high single digits compared to last year and up double digits when excluding the impact of the expected large year-over-year decline in COVID test sales that occurred in the third quarter. Our performance continues to be driven by innovation, positioning Abbott Laboratories to consistently deliver high-quality results and durable long-term value to our shareholders. Recently launched new products generated nearly $5 billion in sales this quarter and added more than 100 basis points to organic sales growth. Looking ahead, we expect increasing contributions from new products across the portfolio with a balanced mix of iterative and transformative innovation. Robert Ford: I'll now summarize our third quarter results in more detail before turning the call over to Philip. And I'll start with Nutrition, where sales increased 4% in the quarter led by the adult nutrition business. Ensure remains the cornerstone of our adult nutrition portfolio, trusted by millions of consumers seeking to maintain or improve their health. Strong brand recognition, combined with favorable demographic and dietary trends, including an increased focus on protein intake and immune system health, continues to fuel our growth. Growth in adult nutrition was driven by 10% growth in international markets, where we continue to see strong demand from both Ensure and Glucerna. To support future growth, we continue to invest in these well-known brands to ensure they evolve along”